2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05218668
(ClinicalTrials.gov)
December 22, 202123/11/2021Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Fasudil (WP-0512)Woolsey PharmaceuticalsNULLRecruiting18 Years75 YearsAll20Phase 2United States;Australia
2EUCTR2017-003676-31-FR
(EUCTR)
31/12/201925/04/2018Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALSInhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS Amyotrophic lateral sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Eril®
INN or Proposed INN: FASUDIL HYDROCHLORIDE
Other descriptive name: FASUDIL HYDROCHLORIDE
Georg-August-Universität GöttingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 2France;Germany;Switzerland
3NCT03792490
(ClinicalTrials.gov)
February 20, 201928/12/2018Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALSInhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALSAmyotrophic Lateral SclerosisDrug: Fasudil;Drug: PlaceboUniversity Medical Center GoettingenNULLRecruiting18 YearsN/AAll120Phase 2France;Germany;Switzerland
4NCT01935518
(ClinicalTrials.gov)
September 20131/9/2013A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)A Historical Placebo Controlled Screening Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: FasudilPeking University Third HospitalNULLRecruiting18 Years70 YearsBoth10Phase 2China